| Cancer statistics, 2016 | Ca-A Cancer Journal for Clinicians | 2016 | 13.1K |
| Cancer statistics in China, 2015 | Ca-A Cancer Journal for Clinicians | 2016 | 11.3K |
| Cancer treatment and survivorship statistics, 2016 | Ca-A Cancer Journal for Clinicians | 2016 | 3.3K |
| Global Cancer Incidence and Mortality Rates and Trends--An Update | Cancer Epidemiology Biomarkers and Prevention | 2016 | 2.1K |
| Long Noncoding RNAs in Cancer Pathways | Cancer Cell | 2016 | 1.9K |
| The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer | Journal of Thoracic Oncology | 2016 | 1.9K |
| The biology and function of fibroblasts in cancer | Nature Reviews Cancer | 2016 | 1.8K |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer | Annals of Oncology | 2016 | 1.7K |
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Nature Reviews Cancer | 2016 | 1.4K |
| Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease | Nature Reviews Clinical Oncology | 2016 | 1.2K |
| Immune-related adverse events with immune checkpoint blockade: a comprehensive review | European Journal of Cancer | 2016 | 1.2K |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Lancet Oncology, The | 2016 | 1.2K |
| CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition | American Journal of Clinical Oncology: Cancer Clinical Trials | 2016 | 1.1K |
| Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial | Journal of Clinical Oncology | 2016 | 1.1K |
| Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial | Lancet Oncology, The | 2016 | 1K |
| Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice | Cell Host and Microbe | 2016 | 975 |
| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study | Lancet Oncology, The | 2016 | 954 |
| Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis | Cancer Cell | 2016 | 931 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial | Lancet Oncology, The | 2016 | 931 |
| Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors | JAMA Oncology | 2016 | 895 |
| YAP/TAZ at the Roots of Cancer | Cancer Cell | 2016 | 886 |
| Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer | Journal of Clinical Oncology | 2016 | 869 |
| Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study | Journal of Clinical Oncology | 2016 | 867 |
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy | Lancet Oncology, The | 2016 | 842 |
| Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy | Cancer Discovery | 2016 | 841 |
